Health Care

Insider buys at uniQure NV reveal CEO confidence in the gene‑therapy pipeline amid falling shares and regulatory pressure – a subtle bullish signal for investors.

Insider buying spurs optimism at Sana Biotechnology—executives’ RSU and option purchases signal confidence ahead of key FDA milestones.

Progyny CFO’s March 4 sale: insider activity, volatile market and analyst sentiment explained – what investors need to know about future stock moves.

Entrada Therapeutics CFO’s disciplined 10b5‑1 insider sales reveal confidence yet little market impact—focus on oncology pipeline, tech gains, and payer deals for long‑term upside.

VSee Health insider buys signal confidence in its low‑price platform, yet investors face high volatility and negative earnings – a speculative yet potentially rewarding small‑cap opportunity.

EyePoint CFO’s sell‑and‑rebuy of 5,000 shares reveals a portfolio‑restructuring move, not a negative signal. The strategy hints at insider confidence amid a 122% YTD stock rally.

Medline insider buying signals confidence amid a volatile secondary offering, pointing to potential upside for investors eyeing healthcare supply stocks.

Insightful analysis of Zai Lab insider trades shows executives buying low, selling high to capture gains while preserving long‑term value—key for investors tracking biotech growth.

Moderna’s legal chief buys shares after a $2.25B patent settlement, showing insider confidence and a clearer IP roadmap for investors.

Orthofix Medical insider sales are routine tax‑cover moves, yet the firm’s strong clinical trials and FDA clearances suggest long‑term growth, reassuring investors and clinicians alike.